Kuvan® in Phenylketonuria Patients Less Than 4 Years Old
Learn more about:
Related Clinical Trial
First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria
Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3)
The Effect of Nursing Empowerment Program
Evaluation of Phe Fluctuation in PKU Pts Treated With PKU GOLIKE Versus Standard Amino Acid Protein Substitute.
Preliminary Study of Brain Effects of Palynziq-Related Changes in Phenylalanine in Individuals With PKU
Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria
Impact of Fruit and Vegetables in PKU
Study to Evaluate the Effect on Nitrogen Retention of Two Different Posology Schemes of PKU GOLIKE PLUS 3-16 and Free AAs in Patients With Phenylketonuria
Safety and Efficacy of HMI-103, a Gene Editing Development Candidate in Adults With Classical PKU Due to PAH Deficiency
Additional Dietary Large Neutral Amino Acids (LNAA) for Improved Symptoms in Adult Classical Phenylktonuria (PKU)
A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria
Metabolic Control and Patient Well-being in Phenylketonuria: do Guidelines Make a Difference?
Evaluation of PKU Sphere Liquid
A Study of PTC923 in Participants With Phenylketonuria
Evaluation of PKU Express Plus
Comparison of Atherogenic Risk Factors and Efficacy of Nutritional Treatment Among Adult Phenylketonuria Patients
Remote Neurocognitive and Psychological Assessment in PKU
Evaluation of PKU Explore France
Study of Low-grade Systemic Inflammation in Adult Patients With Phenylketonuria
Natural History Clinical Study in Adult PKU
Evaluation of PKU Sphere in Italy
Efficacy and Safety of SYNB1618 in Adult Patients With Phenylketonuria
AAV Gene Therapy Study for Subjects With PKU
A Prospective Clinical Study of Phenylketonuria (PKU)
Life With Phenylketonuria. Adult Neurological Outcome of PCU Screened Patients From 1971 to 2002.
Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)
Patient and Observer Reported Outcome Measurements in Inborn Errors of Metabolism
Bone Mineral Density in Adults With Hyperphenylalaninemia
Bone Mineral Density in Adults With Hyperphenylalaninemia on Kuvan Therapy
The Early History of Universal Screening for Metabolic Disorders
Market Research – Acceptability Study for a New PKU Protein Substitute
Market Research – Acceptability Trial for a New PKU Amino Acid Based Protein Substitute
Evaluation of Behavior, Executive Function, Neurotransmitter Function and Genomic Expression Kuvan Nonresponders
The Effectiveness of Kuvan in Amish PKU Patients
An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165
Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKU
Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003)
Study of BH4, a New and Simple Treatment of Mild PKU
Biological Variation of Phenylalanine in Patients With Hyperphenylalaninemia
Testing of Four Home Phenylalanine Monitoring Prototype Devices
Evaluation of PKU Start
Evaluation of PKU Explore
A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects
The Effects of CGMP in Children and Adults With PKU
Nutrition Status of Adults With PKU Before and During Treatment With Pegvaliase
SNAP: Study Nutrients in Adult PKU
Effects of Kuvan on Melatonin Secretion
A Pilot Study on Diurnal Variation
PANDA: PKU Amino Acid Evaluation
A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of CDX 6114 in PKU Patients
Sapropterin Expanded Access Program
Study to Evaluate the Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day Dose) in Adults With PKU
Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU
PKU Skin Stripping
A Phase 3 Substudy to Evaluate Executive Function in Adults With PKU Who Are Participating in the Phase 3 Study, 165-302
Gene Therapy Clinical Study in Adult PKU
Study of Phenoptin to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet
Follow-up of Adult Phenylketonuria (PKU) Patients
PKU Low Calorie Drink Study
A 16 Week Study Evaluating the Introduction of a GMP Based Protein Substitute in Participants With PKU
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 Weeks
Nutrition Status of Adults Treated With Pegvaliase
Phase 2 Study of Glycomacropeptide Versus Amino Acid Diet for Management of Phenylketonuria
An Observational, Cross-sectional Study Into the Future Cardiovascular Disease (CVD) Risk of Phenylketonuria (PKU) Patients on a Low Phenylalanine Treatment Diet (LPD).
GMP Drink for PKU Study
Nutritional and Neurotransmitter Changes in PKU Subjects on BH4
Evaluation of PKU Sphere
Neurocognitive Outcomes in Mild Hyperphenylalaninemia (MHP)MHP Study
Long-Term Tetrahydrobiopterin Treatment in PKU Patients of 0-18 Years – Study on Phenylalanine Tolerance and Safety
Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan Response
Study of a Phenylalanine Restricted Diet During Pregnancy to Prevent Symptoms in Offspring of Patients With Phenylketonuria
Safety and Tolerability of RTX-134 in Adults With Phenylketonuria
Effects of Synergy on Nutrient Intake and Acceptability in Phenylketonuria (PKU)
Safety and Tolerability Study of rAvPAL-PEG to Treat Phenylketonuria
Safety, Tolerability, and Efficacy Study of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria (PKU)
Phenylalanine and Its Impact on Cognition
A Non-Interventional Interview Study of Phenylketonuria (PKU) Adults
Long-Term Follow Up Study of Subjects Previously Administered HMI 102
Safety and Tolerability of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With Phenylketonuria
PKUDOS: Phenylketonuria (PKU) Demographic, Outcomes, and Safety Registry
The Effect of Supplemental Docosahexaenoic Acid (DHA) on Neurocognitive Outcomes in Teen and Adult Women With Phenylketonuria(PKU)
Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients
Simple Breath Test to Examine Phenylalanine Metabolism
MRI Spectroscopy and Neuropsychological Functioning in Phenylketonuria
Body Composition, Energy Intake and Expenditure in People With Phenylketonuria
Response to Kuvan® in Subjects With Phenylketonuria (PKU) in a 4 Weeks Testing Period
Simplified Diet Approach in Phenylketonuria
Study to Evaluate the Safety and Efficacy of Phenoptin™ in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels
Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of CDX-6114 in Patients With Phenylketonuria (PKU)
Short-term Effects of Good Metabolic Control on Cognitive Function, Wellbeing, and Metabolic Parameters in Adult Patients With Phenylketonuria
Study to Evaluate the Response to and Safety of an 8-Day Course of Phenoptin™ Treatment in Subjects With Phenylketonuria
The Brain and Neuropsychological Functioning in Adults With Sapropterin Dihydrochloride Treated Phenylketonuria
The Effects of Kuvan on Functional Brain Connectivity in Individuals With Phenylketonuria (PKU)
The Brain, Neurological Features and Neuropsychological Functioning in Adults With Phenylketonuria: A Pilot Study
Protein Requirements in Adults With Phenylketonuria (PKU)
Moderate Intensity Exercise and Phenylketonuria
Compliance, Tolerance and Acceptability of a Tablet Protein Substitute for the Dietary Management of Phenylketonuria
Study to Evaluate the Effects of Kuvan on Individuals With Phenylketonuria (PKU) With Maladaptive Behaviors
Study of Phenoptin in Subjects With Phenylketonuria Who Participated in Protocols PKU-004 or PKU-006
Fluorodeoxyglucose Positron Emission Tomography (FDG PET) Findings in Patients With Phenylketonuria Before and After KUVAN Therapy
Protein Requirements in Children With Phenylketonuria (PKU)
Kuvan®’s Effect on the Cognition of Children With Phenylketonuria
Phenylketonuria, Oxidative Stress, and BH4
Quantitative Requirements of Docosahexaenoic Acid for Neural Function in Children With Phenylketonuria
Sapropterin on Cognitive Abilities in Young Adults With Phenylketonuria
Evaluating the Efficacy of PKU Synergy in Patients Expressing Phenylketonuria or Hyperphenylalaninemia
Kuvan® in Phenylketonuria Patients Less Than 4 Years Old
BH4 Responsiveness in PAH Deficiency PKU Patients
Response to Phenylketonuria to Tetrahydrobiopterin (BH4)
Behavioral Effects of Kuvan in Children With Mild Phenylketonuria
Impact of Phenylketonuria-type Diet on Appetite, Appetite Hormones and Diet Induced Thermogenesis
Nutritional Status in Phenylketonuria
Early Dietary Treated Patients With Phenylketonuria Can Achieve Normal Growth and Mental Development.
Liver Cell Transplant for Phenylketonuria
Sapropterin in Individuals With Phenylketonuria
Phase 3 Open-label Study to Evaluate the Response and Safety of Kuvan® in Subjects With Phenylketonuria
Observational Study of Endothelial Dysfunction in Phenylketonuria